Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 5/2006

01-03-2006 | Review

Scleroderma associated with ANCA-associated vasculitis

Authors: Young Hee Rho, Seong Jae Choi, Young Ho Lee, Jong Dae Ji, Gwan Gyu Song

Published in: Rheumatology International | Issue 5/2006

Login to get access

Abstract

We have recently reported on two cases of scleroderma patients with ANCA-associated vasculitis for the first time in Korea. In order to explore the nature of this disease combination, we pooled together all the previously known cases and statistically analyzed them. Out of the 50 selected cases, survival analysis was done for comparison of the scleroderma disease period and the clinical factors associated with ANCA-associated vasculitis (AAV). Kaplan-Meier analysis revealed that patients having anti-topoisomerase antibody (anti-Scl-70) and, probably, PR-3 ANCA are at a higher risk for developing AAV than patients without both anti-topoisomerase antibody and anti-centromere antibody (ACA), and patients with MPO-ANCA. Multivariate Cox regression analysis revealed having anti-topoisomerase antibody as a risk factor for developing AAV [OR 3.1 (95% CI 1.11–8.55), P=0.031]. We suggest that having anti-topoisomerase antibodies may play a role among scleroderma patients in developing AAV.
Literature
1.
Endo H, Hosono T, Kondo H (1994) Antineutrophil cytoplasmic autoantibodies in 6 patients with renal failure and systemic sclerosis. J Rheumatol 21:864–870PubMed
2.
Akimoto S, Ishikawa O, Tamura T, Miyachi Y (1996) Antineutrophil cytoplasmic autoantibodies in patients with systemic sclerosis. Br J Dermatol 134:407–410PubMedCrossRef
3.
Kiraz S, Simsek H, Ertenli I, Benekli M, Kadayifci A (1996) Antineutrophil cytoplasmic antibodies in systemic sclerosis. Clin Rheumatol 15:519–520PubMedCrossRef
4.
Locke IC, Worrall JG, Leaker B, Black CM, Cambridge G (1997) Autoantibodies to myeloperoxidase in systemic sclerosis. J Rheumatol 24:86–89PubMed
5.
Bellisai F, Morozzi G, Bacarelli MR, Radice A, Sinico RA, Wieslander J, Sebastiani GD, Campanella V, Marcolongo R, Galeazzi M (2001) Anti-proteinase 3 antibodies in diffuse systemic sclerosis (SSc) with normotensive renal impairment: is it suggestive for an overlapping between SSc and idiopathic vasculitis? Reumatismo 53:33–39PubMed
6.
Casari S, Haeney M, Farrand S, Herrick A (2002) Antineutrophil cytoplasmic antibodies a "Red Flag" in patients with systemic sclerosis. J Rheumatol 29:2666–2667PubMed
7.
Caramaschi P, Biasi D, Tonolli E, Carletto A, Bambara LM (2002) Antineutrophil cytoplasmic antibodies in scleroderma patients: first report of a case with anti-proteinase 3 antibodies and review of the literature. Joint Bone Spine 69:177–180PubMedCrossRef
8.
Ruffatti A, Sinico RA, Radice A, Ossi E, Cozzi F, Tonello M, Grypiotis P, Todesco S (2002) Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol 29:918–923PubMed
9.
Rho YH, Choi SJ, Ji JD, Lee YH, Song GG (2005) Scleroderma associated with ANCA-associated vasculitis. A case report. Rheumatol Int (in submission). DOI 10.1007/s00296-005-0003-5
10.
Le Thi Huong D, Gatfosse M, Papo T, Beaufils H, Faucher C, Frances C, Godeau P (1994) Wegener’s granulomatosis and CREST syndrome. Br J Rheumatol 33:1087–1088CrossRef
11.
Kobayashi M, Saito M, Minoshima S, Arimura Y, Nagasawa T (1995) A case of progressive systemic sclerosis with crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) and anti-glomerular basement membrane antibody (anti-GBM Ab). Nippon Jinzo Gakkai Shi 37:207–211PubMed
12.
Vazquez-Del Mercado M, Mendoza-Topete A, Best-Aguilera CR, Garcia-De La Torre I (1996) Diffuse alveolar hemorrhage in limited cutaneous systemic sclerosis with positive perinuclear antineutrophil cytoplasmic antibodies. J Rheumatol 23:1821–1823PubMed
13.
Carvajal I, Bernis C, Sanz P, Garcia A, Garcia-Vadillo A, Traver JA (1997) Antineutrophil cytoplasmic autoantibodies (ANCA) and systemic sclerosis. Nephrol Dial Transplant 12:576–577PubMedCrossRef
14.
Hillis GS, Khan IH, Simpson JG, Rees AJ (1997) Scleroderma, D-penicillamine treatment, and progressive renal failure associated with positive antimyeloperoxidase antineutrophil cytoplasmic antibodies. Am J Kidney Dis 30:279–281PubMed
15.
Karpinski J, Jothy S, Radoux V, Levy M, Baran D (1997) D-penicillamine-induced crescentic glomerulonephritis and antimyeloperoxidase antibodies in a patient with scleroderma. Case report and review of the literature. Am J Nephrol 17:528–532PubMedCrossRef
16.
Omote A, Muramatsu M, Sugimoto Y, Hosono S, Murakami R, Tanaka H, Watanabe Y, Sano H, Kato K (1997) Myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibodies-related scleroderma renal crisis treated with double-filtration plasmapheresis. Intern Med 36:508–513PubMedCrossRef
17.
Uriuhara A, Morita S, Yamada K, Masugi J, Yamada H, Hasegawa Y, Yokono K, Kasuga M (1997) A case of MPO-ANCA positive progressive systemic sclerosis with status epileptics. Ryumachi 37:483–486PubMed
18.
Marchand-Courville S, Dhib M, Fillastre JP, Godin M (1998) Extracapillary glomerulonephritis secondary to D-penicillamine. Apropos of 1 case and review of the literature. Nephrologie 19:25–32PubMed
19.
Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlondorff D (1999) MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am J Kidney Dis 33:e3PubMed
20.
Harashima S, Yoshizawa S, Horiuchi T, Nakashima H, Niho Y, Kusaba T, Hayashida I, Shinozaki M, Katafuchi R, Hirakata H (1999) A case of systemic sclerosis with crescentic glomerulonephritis associated with perinuclear-antineutrophil cytoplasmic antibody (p-ANCA). Nihon Rinsho Meneki Gakkai Kaishi 22:86–92PubMed
21.
Katrib A, Sturgess A, Bertouch JV (1999) Systemic sclerosis and antineutrophil cytoplasmic autoantibody-associated renal failure. Rheumatol Int 19:61–63PubMedCrossRef
22.
Kyndt X, Ducq P, Bridoux F, Reumaux D, Makdassi R, Gheerbrant JD, Vanhille P (1999) Extracapillary glomerulonephritis with anti-myeloperoxidase antibodies in 2 patients with systemic scleroderma treated with penicillamine D. Presse Med 28:67–70PubMed
23.
Villaverde V, Balsa A, Cabezas JA, Fernandez-Prada M, Torre A, Mola EM (1999) Normotensive renal failure in a patient with systemic sclerosis and p-antineutrophil cytoplasmic autoantibodies which developed into Paget’s disease of bone after immunosuppressive therapy. Rheumatology (Oxford) 38:190–191CrossRef
24.
Maes B, Van Mieghem A, Messiaen T, Kuypers D, Van Damme B, Vanrenterghem Y (2000) Limited cutaneous systemic sclerosis associated with MPO-ANCA positive renal small vessel vasculitis of the microscopic polyangiitis type. Am J Kidney Dis 36:E16PubMed
25.
Martinez Ara J, Picazo ML, Torre A, Pascual D, Diaz Rodriguez C, Rinon C (2000) Progressive systemic sclerosis associated with anti-myeloperoxidase ANCA vasculitis with renal and cutaneous involvement. Nefrologia 20:383–386PubMed
26.
Mizutani A, Tanaka I, Katayama M, Oshima H, Komatsu Y, Asano S, Kato K, Matsumura H, Ishii K, Miyama H, Nagai T, Fukaya S, Yoshida S, Hasegawa M, Kawashima S, Torikai K (2000) A case of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) related glomerulonephritis associated with systemic sclerosis treated by steroid pulse therapy: a case report. Ryumachi 40:828–832PubMed
27.
Yamashita K, Yorioka N, Kyuden Y, Naito T, Tanji C, Ueda C, Usui K, Shigemoto K, Harada S, Yamakido M (2000) A case of CREST syndrome and myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Clin Nephrol 53:296–300PubMed
28.
Wutzl AL, Foley RN, O’Driscoll BR, Reeve RS, Chisholm R, Herrick AL (2001) Microscopic polyangiitis presenting as pulmonary-renal syndrome in a patient with long-standing diffuse cutaneous systemic sclerosis and antibodies to myeloperoxidase. Arthritis Rheum 45:533–536PubMedCrossRef
29.
Kumakura S, Ishikura H, Kondo M, Murakawa Y, Kobayashi S (2002) Hemophagocytosis associated with MPO-ANCA positive vasculitis in systemic sclerosis. Clin Exp Rheumatol 20:411–414PubMed
30.
Miyamura T, Yamamoto M, Shimada H, Suematsu E (2002) Systemic sclerosis associated with microscopic polyangitis presenting with high myeloperoxidase (MPO) titer and necrotizing angitis: a case report. Ryumachi 42:910–914PubMed
31.
Miyata N, Kobayashi T, Matsukawa Y, Sawada S, Nishinarita S, Horie T (2002) Anti-neutrophil cytoplasmic autoantibody-associated rapid progressive glomerulonephritis complicated with both limited and diffuse scleroderma. Nihon Rinsho Meneki Gakkai Kaishi 25:473–479PubMed
32.
Tomioka M, Hinoshita F, Miyauchi N, Akiyama Y, Saima S, Hiroe M (2004) ANCA-related crescentic glomerulonephritis in a patient with scleroderma without marked dermatological change and malignant hypertension. Intern Med 43:496–502PubMedCrossRef
33.
Wigley FM, Hummers LK (2003) Clinical features of systemic sclerosis. In: Hochberg MC, Silman AJ, Smolen JS, Wienblatt ME, Weismann MH (eds) Rheumatology, 3rd ed. Edinburgh, Mosby, pp 1463–1477
34.
35.
Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, Harley JB (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526–1533PubMedCrossRef
36.
Homma S, Matsushita H, Nakata K (2004) Pulmonary fibrosis in myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitides. Respirology 9:190–196PubMedCrossRef
37.
Lhote F, Cohen P, Genereau T, Gayraud M, Guillevin L (1996) Microscopic polyangiitis: clinical aspects and treatment. Ann Med Interne (Paris) 147:165–177
38.
Gaudin PB, Askin FB, Falk RJ, Jennette JC (1995) The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase. Am J Clin Pathol 104:7–16PubMed
39.
Nada AK, Torres VE, Ryu JH, Lie JT, Holley KE (1990) Pulmonary fibrosis as an unusual clinical manifestation of a pulmonary-renal vasculitis in elderly patients. Mayo Clin Proc 65:847–856PubMed
40.
Eschun GM, Mink SN, Sharma S (2003) Pulmonary interstitial fibrosis as a presenting manifestation in perinuclear antineutrophilic cytoplasmic antibody microscopic polyangiitis. Chest 123:297–301PubMedCrossRef
41.
42.
Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113:352–357PubMed
43.
Steen VD, Medsger TA Jr (1998) Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 41:1613–1619PubMedCrossRef
44.
Khanna D, Aggarwal A, Bhakuni DS, Dayal R, Misra R (2003) Bactericidal/permeability-increasing protein and cathepsin G are the major antigenic targets of antineutrophil cytoplasmic autoantibodies in systemic sclerosis. J Rheumatol 30:1248–1252PubMed
Metadata
Title
Scleroderma associated with ANCA-associated vasculitis
Authors
Young Hee Rho
Seong Jae Choi
Young Ho Lee
Jong Dae Ji
Gwan Gyu Song
Publication date
01-03-2006
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 5/2006
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-005-0011-5

Other articles of this Issue 5/2006

Rheumatology International 5/2006 Go to the issue

Original Article

Magnetic resonance imaging guided corticosteroid injection of sacroiliac joints in patients with spondylarthropathy. Are multiple injections more beneficial?

Original Article

The use of the hand anatomic index to assess deformity and impaired function in systemic sclerosis

Original Article

Pilot clinical study of Adacolumn cytapheresis in patients with systemic lupus erythematosus

Original Article

HgCl2 challenge in Brown Norway rats lead to dermatitis instead of arthritis

Case Report

Nocardiosis in a patient with primary anti-phospholipid syndrome

Original Article

Prevalence of antibodies against oxidised LDL in a cohort of 163 patients with positive anti-phospholipid antibodies and recent thrombosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits